- Home
- ACRS vs IDR Comparison
ACRS vs IDR Comparison
Compare ACRS & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- IDR
- Stock Information
- Founded
- ACRS 2012
- IDR 1996
- Country
- ACRS United States
- IDR United States
- Employees
- ACRS N/A
- IDR N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- IDR Precious Metals
- Sector
- ACRS Health Care
- IDR Basic Materials
- Exchange
- ACRS Nasdaq
- IDR Nasdaq
- Market Cap
- ACRS 165.7M
- IDR 180.8M
- IPO Year
- ACRS 2015
- IDR N/A
- Fundamental
- Price
- ACRS $1.59
- IDR $16.75
- Analyst Decision
- ACRS Strong Buy
- IDR Strong Buy
- Analyst Count
- ACRS 9
- IDR 1
- Target Price
- ACRS $9.25
- IDR $17.50
- AVG Volume (30 Days)
- ACRS 1.3M
- IDR 451.8K
- Earning Date
- ACRS 08-06-2025
- IDR 07-29-2025
- Dividend Yield
- ACRS N/A
- IDR N/A
- EPS Growth
- ACRS N/A
- IDR 144.40
- EPS
- ACRS N/A
- IDR 0.62
- Revenue
- ACRS $17,777,000.00
- IDR $27,144,971.00
- Revenue This Year
- ACRS N/A
- IDR $9.76
- Revenue Next Year
- ACRS $11.77
- IDR N/A
- P/E Ratio
- ACRS N/A
- IDR $27.07
- Revenue Growth
- ACRS N/A
- IDR 67.42
- 52 Week Low
- ACRS $1.05
- IDR $9.58
- 52 Week High
- ACRS $5.17
- IDR $19.75
- Technical
- Relative Strength Index (RSI)
- ACRS 59.88
- IDR 72.59
- Support Level
- ACRS $1.44
- IDR $12.41
- Resistance Level
- ACRS $1.52
- IDR $13.40
- Average True Range (ATR)
- ACRS 0.10
- IDR 0.73
- MACD
- ACRS 0.00
- IDR 0.35
- Stochastic Oscillator
- ACRS 79.17
- IDR 93.81
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.